Company intelligence / Profile preview

Myconostica

Cambridge, United Kingdommyconostica.co.uk ↗

Ownership: Private
Development stage: Commercial

Overview

Myconostica developed rapid molecular diagnostic tests for life-threatening invasive fungal infections. Its CE-marked products demonstrated improved sensitivity and speed over traditional culture methods. Clinical trials validated the performance of its lead assays for detecting Aspergillus and Pneumocystis jirovecii directly from patient samples. The company was acquired by Lab21 in May 2011 to expand Lab21’s infectious disease diagnostics portfolio.

Therapeutic areas: Infectious Diseases
Modalities: Molecular diagnostic testDeviceNucleic acid-based assay
Industry: Molecular Diagnostics

Partnerships

BD Diagnostics/Becton DickinsonUniversity Hospital of South Manchester

Beyond the preview

Go deeper on Myconostica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myconostica.

Explore the full profile